Literature DB >> 9284661

Management of chronic hepatitis C: clinical audit of biopsy based management algorithm.

G R Foster1, R D Goldin, J Main, I Murray-Lyon, S Hargreaves, H C Thomas.   

Abstract

OBJECTIVE: To assess the attendance, outcome, compliance with treatment, and response to interferon alfa in patients with chronic hepatitis C who attended during 1995 and were treated according to a biopsy based algorithm.
DESIGN: Retrospective audit of all patients with chronic hepatitis C attending outpatient clinics over one year.
SETTING: The liver unit at a London teaching hospital.
SUBJECTS: 255 patients with chronic hepatitis C. MAIN OUTCOME MEASURES: Patient survival, attendance, and compliance with diagnostic and therapeutic regimens. Response to interferon alfa treatment, based on loss of viraemia three months after cessation of treatment.
RESULTS: A large proportion of patients (39%) with newly diagnosed chronic hepatitis C infection do not want to undergo further investigation. Of those patients who do attend for further treatment, a large proportion with severe hepatic fibrosis (42%) do not want to undergo currently available treatment. The response rate to interferon (21%) in treated patients was similar to that previously reported in a trial setting. There was no significant difference in response rates in patients with or without severe fibrosis not amounting to cirrhosis. In patients with cirrhosis there was a high incidence of hepatocellular carcinoma (18%) over a follow up period of 20 months.
CONCLUSION: Current strategies aimed at investigating and treating patients with chronic hepatitis C are not acceptable to a large proportion of patients. Many patients with cirrhosis related to hepatitis C infection develop hepatic neoplasms, and management strategies to deal with this problem are urgently required.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284661      PMCID: PMC2127336          DOI: 10.1136/bmj.315.7106.453

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  20 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 2.  Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

Authors:  John B Wong
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  The epidemiology of hepatitis C in a UK health regional population of 5.12 million.

Authors:  A H Mohsen
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

4.  The portal component of hepatic perfusion measured by dynamic CT: an indicator of hepatic parenchymal damage.

Authors:  Y Tsushima; J K Blomley; S Kusano; K Endo
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

Review 5.  Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.

Authors:  Elliot B Tapper; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-02-21       Impact factor: 46.802

6.  Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants.

Authors:  Cynthia Hsu; Cyrielle Caussy; Kento Imajo; Jun Chen; Siddharth Singh; Kellee Kaulback; Minh-Da Le; Jonathan Hooker; Xin Tu; Ricki Bettencourt; Meng Yin; Claude B Sirlin; Richard L Ehman; Atsushi Nakajima; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

7.  In vivo, high-field, 3-Tesla 1H MR spectroscopic assessment of liver fibrosis in HCV-correlated chronic liver disease.

Authors:  A Orlacchio; F Bolacchi; M Angelico; A Mancini; V Cozzolino; M Cadioli; G Simonetti
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

8.  Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study.

Authors:  M J K Blomley; A K P Lim; C J Harvey; N Patel; R J Eckersley; R Basilico; R Heckemann; A Urbank; D O Cosgrove; S D Taylor-Robinson
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

9.  The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Elliot B Tapper; Tracy Challies; Imad Nasser; Nezam H Afdhal; Michelle Lai
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

10.  Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients.

Authors:  Maciej Witkos; Qi-Long Yi; Jenny Heathcote; Moira K Kapral; Murray D Krahn
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.